“…Among them, regorafenib is a novel orally active multitarget compound that inhibits a number of pro-angiogenic TK receptors, including FGFR1, VEGFR2, TIE2, and PDGFR [143]; nintedanib (BIBF1120) interferes with VEGFR, PDGFR and FGFR pathways [144]; ponatinib (AP24534), mainly active on BCR-ABL, has been described to exert an anti-FGFR activity in vitro [145]. Several other small molecules, including axitinib, brivanib, cabozantinib, dovotinib, oratinib, pazopamib, sorafenib, sunitinib and vandetanib are endowed with this non-selective TKI profile (see Refs.…”